Practical pharmaceutical and healthcare intelligence across Europe, GCC, and MENA.
114
Published articles
EMEA
Regional coverage
◈
Fieldwork-led insights
Connect product strategy with market evidence—from physician surveys and payer interviews to patient journey work and GCC access scenarios.
Pick articles that match your decision stage—pre-launch, pricing, or post-launch—then follow through to healthcare market research and service pages for a coherent evidence thread.
114 articles
China medical device VBP rounds explained for 2026: stent and joint price-cut examples, win vs lose outcomes, renewals, localization scoring, and private-hospital escape valves.
NMPA Class III medical device registration timeline 2026: CMDE review, clinical evaluation options, Resident Agent duties, and 18–36 month planning bands for China launch sequencing.
Singapore's medtech industry in 2026: manufacturing scale (top-30 global device makers, 60% of world microarrays), HSA Class A–D registration, Access Consortium, and the companies with real Singapore plants.
Turkey's pharmaceutical market in 2026: size and growth (IMARC: USD 10.5B in 2025 to USD 15.6B by 2035), TITCK's CTD/OAS registration process, five-country reference pricing, and the leading local and multinational companies.
Egypt is the largest consumer and pharmaceutical market in North Africa. This guide compares the global networks and healthcare-focused firms with a verifiable Egypt presence.
Saudi Arabia's SFDA and NUPCO reviews reward dossiers built on local evidence, not adapted global templates. Here is how BioNixus structures HTA-ready submissions — from epidemiology and comparator se
Compare top healthcare market research companies for pharmaceutical and medtech teams in 2026: services, evaluation scorecards, global vs specialist trade-offs, BioNixus GCC/Europe depth, and how to c
A procurement-style guide to healthcare market research across MENA, GCC, UK, and Europe: why regional expertise matters, how to evaluate specialist firms including BioNixus, services from physician i
In March 2026, the UAE launched a unified GCC drug registration platform enabling access to six Middle Eastern markets with a single submission—compressing timelines from 12-18 months to 6-8 months. T
In April 2026, the EMA streamlined its orphan drug designation process—reducing average decision times to 90 days. This comprehensive guide decodes EMA's updates and provides actionable strategies for
In March 2026, the FDA approved the first fully AI-designed drug molecule for Phase 3 trials. This comprehensive guide provides strategic roadmap for integrating AI into drug discovery, backed by anal
Saudi Arabia's SFDA fast-track cuts approval to 7 months while UAE harmonizes 85% of requirements with GCC-DR. This comprehensive guide provides actionable intelligence on the $35B GCC pharmaceutical
A data-accurate 2026 guide to Regulation (EU) 2021/2282: phased Joint Clinical Assessment from January 2025 for oncology and ATMPs, 2028 for orphans, 2030 for remaining centrally authorised products,
A data-accurate 2026 guide to FDA real-world evidence for pharmaceutical submissions: the 21st Century Cures Act mandate, FDA’s 2018 RWE Framework, finalized RWD/RWE guidances, when RWE can support la
A 2026 guide to oncology market research in the USA: CMS EOM, NCCN pathways, FDA vs payer evidence, KOL advisory boards, and claims data cautions.
How pharmacoeconomics consulting supports European payer negotiations in 2026: CEA, BIA, and country-specific HEOR requirements in Germany, France, and Spain.
A 2026 guide to market access research in the UAE: EDE federal pricing, DoH and DHA payer rules, reimbursement research, and launch tracking for pharmaceutical teams.
How FDA's real-world evidence framework, payer expectations, and RWE study design choices shape pharmaceutical market access in the United States in 2026.
A 2026 guide to EU HTA Regulation, joint clinical assessment, real-world evidence expectations, and how primary research supports pharmaceutical market access across Europe.
A practical 2026 guide to building a Saudi budget impact model for SFDA economic evaluation, covering payer perspective, local epidemiology, NUPCO context, and common failure modes.
AbbVie's Skyrizi led July pharma TV ad spend and brand-impression rankings. Here is what that leadership signals for omnichannel engagement, HCP digital, and measuring promotional ROI beyond impressions.
A consultant-style guide to the Saudi Arabia in vitro diagnostics market: BioNixus market sizing, test segments, molecular diagnostics and genomics, SFDA MDMA registration via GHAD, NUPCO and referenc
A procurement-style guide to Kuwait healthcare market research: CMS tender context, MOPH registration realities, global versus specialist trade-offs, syndicated data complements, compliance expectatio
All three major U.S. PBMs agree to cover Lilly’s expanded obesity portfolio including Foundayo and Zepbound.
FDA extends PDUFA for camizestrant combination NDA to review supplemental clinical data in ER+ breast cancer.
FDA approves pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Desmoid tumour/fibromatosis landscape, gamma secretase inhibitor OGSIVEO (nirogacestat) FDA approval 27 Nov 2023 for progressing adults—commercial intelligence analogue analogies versus historic off-label systemic regimens.
Neurofibromatosis type 1 tumour burden, oral MEK inhibition—FDA approvals for paediatrics (Apr 2020; expanded ≥1 y Sept 2025) and adults (Nov 2025)—EU EZMEKLY (mirdametinib) conditional approval 17 Jul 2025. Commercial research design for specialists, carers, tenders, analogue analogies.
Koselugo (selumetinib) market research for NF1 plexiform neurofibromas—FDA milestones, EU MEK competition, launch economics, and specialist adoption intelligence.
Eli Lilly commits ~$4B to acquire Curevo, LimmaTech, and Vaccine Company assets.
FDA grants accelerated approval for bulevirtide in chronic hepatitis delta virus infection.
FDA approves datopotamab deruxtecan for unresectable or metastatic triple-negative breast cancer.
CHMP backs alpelisib for severe PIK3CA-related overgrowth spectrum (PROS).
CHMP recommends approval of nerandomilast for IPF and progressive pulmonary fibrosis.
Complete guide to the GCC clinical trials market in 2026 — regulatory frameworks by country, key trial sites, therapeutic area activity, patient recruitment considerations, and how pharmaceutical and
A complete guide to pharmaceutical market research methods in MENA — quantitative physician surveys, hospital sales data, KOL mapping, market access research, and how data is collected across Saudi Ar
Complete guide to the Saudi Arabia healthcare market in 2026 — pharmaceutical market size, NUPCO procurement, SFDA registration, hospital landscape, Vision 2030 healthcare reforms, and market access f
Comprehensive analysis of the GCC pharmacy market in 2026 — total market size, pharmaceutical sales by country, retail and hospital pharmacy dynamics, generic uptake, biosimilars, and growth forecasts
Comprehensive overview of the UAE healthcare market in 2026 — hospital sales data, pharmaceutical market size, DHA and MOHAP regulatory landscape, private sector growth, and market access for pharmace
FDA approves baxdrostat, first-in-class aldosterone synthase inhibitor for refractory hypertension.
A comprehensive guide to leveraging market research and marketing automation to grow pharmacy retail sales in Saudi Arabia. Covers key players (Nahdi, Al-Dawaa, United Pharmacies), SFDA compliance, Vi
FDA accelerates sonrotoclax for relapsed/refractory mantle cell lymphoma.
FDA approves interchangeable biosimilar insulin glargine referencing Lantus.
CHMP recommends plozasiran for familial chylomicronemia syndrome.
CHMP opinion extends onasemnogene formulation positioning in spinal muscular atrophy.
CHMP positive opinion for tolebrutinib in non-relapsing secondary progressive MS.
FDA approves once-daily two-drug HIV maintenance regimen doravirine/islatravir.
FDA converts Tecartus to full approval in relapsed/refractory mantle cell lymphoma.
An independent guide to the 5 leading market research companies operating in Egypt for 2026 — healthcare, pharma, and consumer research firms compared by methodology, Egypt expertise, EDA awareness, a
A procurement-style overview of healthcare market research in Saudi Arabia: why local insight matters under Vision 2030, how to evaluate partners, representative firm archetypes including BioNixus alo
Independent 2026 guide: 5 leading healthcare market research firms in the UAE compared by pharma depth, DHA/DOH awareness, Arabic fieldwork, and methodology. Includes comparison table, selection crite
A consultant-style guide to digital therapeutics regulation in MENA: GCC SaMD pathways, SFDA and UAE authority structures, North African developments, clinical evidence, reimbursement, data privacy, K
Vasa partners with Lilly TuneLab on AI-driven CAMKII inhibitor discovery.
Roche agrees to acquire PathAI for AI-enabled digital pathology integration.
GoodRx and Lilly expand self-pay Zepbound KwikPen access outside traditional PBM tiers.
FDA approves Foundayo (orforglipron), first oral small-molecule GLP-1 for chronic weight management.
FDA accelerates marnetegragene autotemcel for pediatric severe LAD-I.
CHMP opinion under exceptional circumstances for leniolisib in APDS.
CHMP recommends lurbinectedin maintenance in extensive-stage SCLC.
CHMP backs tarlatamab for relapsed extensive-stage small cell lung cancer.
CHMP positive opinion for nadofaragene in BCG-unresponsive NMIBC.
FDA approves Awiqli, first once-weekly basal insulin for type 2 diabetes.
FDA approves relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer.
FDA approves linerixibat for cholestatic pruritus in primary biliary cholangitis.
FDA approves icotrokinra, first oral peptide targeting IL-23 receptor for plaque psoriasis.
Quantitative healthcare market research in UAE helps pharmaceutical teams convert physician and stakeholder feedback into measurable strategy. This guide covers sample design, validation controls, and
Quantitative healthcare market research in KSA requires robust survey design, verified HCP sampling, and defensible QA controls. This guide shows how pharma teams can translate KSA evidence into stron
The GCC pharmaceuticals market is entering a new growth phase driven by specialty therapies, regulatory modernization, and evolving payer dynamics. This guide explains market size structure, country-l
Pharmaceutical companies face unprecedented pressure to demonstrate value, optimize market access, and navigate complex regulatory landscapes and as a result, quantitative market research has evolved
First interchangeable generic fluticasone MDI approved, triggering formulary shifts.
The UAE is not a monolithic pharmaceutical market. Winning formulary access requires mastering the distinct regulatory, insurance, and clinical pathways of Abu Dhabi’s DOH and Dubai’s DHA. Here is you
How GCC pharmacoeconomics differs from EU HTA, which evidence Saudi and UAE payers weight, and how to assemble tender-ready pharmacoeconomic dossiers with BioNixus HEOR + research coverage.
Mastering the National Unified Procurement Company (NUPCO) tendering process is the gateway to institutional market access in Saudi Arabia. Here is what pharmaceutical leaders must know for 2026.
A deep-dive analysis into how a major regional conflict in 2026 would disrupt currency stability, oil dependencies, and the healthcare supply chain across the GCC, Egypt, and the Levant.
The ultimate compilation of verified healthcare statistics for the Middle East in 2026. Discover market size, pharmaceutical spending, diabetes prevalence, oncology growth, and hospital infrastructure
A detailed methodology for mapping the patient journey within the Saudi Arabian healthcare system. Understand cultural nuances, caregiver influence, and public vs. private pathways.
A comprehensive guide for pharmaceutical companies navigating the National Institute for Health and Care Excellence (NICE) Health Technology Assessment (HTA) process in the UK.
A strategic guide to pharmaceutical competitive intelligence (CI) in the GCC. Learn how to track competitor formularies, pricing strategies, and P&T committee decisions in the Middle East.
A strategic blueprint for pharmaceutical companies entering Saudi Arabia. Learn about localization requirements (NUPCO), distributor selection, direct investment, and regulatory navigation.
Analyze the fastest-growing therapeutic segments in the Saudi Arabian pharmaceutical market for 2026, driven by Vision 2030 and shifting demographic health profiles.
A complete guide to pharmaceutical market access in the UAE. Understand the distinct regulatory pathways, pricing mechanisms, and formulary access strategies via DOH, DHA, and MOHAP.
A comprehensive guide on designing effective Key Opinion Leader (KOL) mapping studies in Saudi Arabia, the UAE, and the wider Middle East for pharmaceutical companies.
A deep dive into pharmaceutical research methods in the Middle East. Compare CATI, CAPI, and Online methodologies for engaging healthcare professionals in Saudi Arabia, UAE, and the wider GCC.
A comprehensive guide for pharmaceutical companies navigating the SFDA drug registration process in Saudi Arabia, covering pathways, timelines, costs, and regulatory strategy.
The Shift to "Always-On" Quantitative Tracking: Why Periodic Studies Are Dying: GCC and multinational market access, payer strategy, and healthcare market
In healthcare quantitative research, compliance is no longer only legal hygiene—it is a trust and competitiveness issue. Buyers increasingly evaluate vendors on privacy-by-design maturity before award
The Recruitment Constraint in Modern Oncology Research Oncology quantitative studies increasingly require niche respondents: tumor-board decision makers, sub-specialized oncologists, pediat
The MedTech Pricing Decision Most Teams Get Wrong When MedTech companies evaluate pricing architecture, many teams ask, “Should we run MaxDiff or Conjoint?” The better question is: “What de
Why Data Validation Became a Board-Level Issue In 2026, quantitative studies in pharmaceutical and MedTech markets face a new integrity threat: AI-assisted response fraud at scale. Traditio
As Saudi Arabia and the UAE accelerate their Vision 2030 and Dubai Economic Agenda (D33) goals, 'pharmaceutical healthcare market research' has become the cornerstone of regional commercial success. I
European healthcare systems are navigating a critical shift toward value-based care and AI integration. This article explores how healthcare market research Europe provides the strategic roadmap for m
The modernization of European hospital infrastructure is creating a $12B opportunity for medtech. Hospital market research is the key to understanding procurement shifts and the rise of value-based he
Explore the key trends shaping Kuwait's healthcare market in 2026 — from Vision 2035 investments and digital health transformation to private sector growth, hospital expansions, and pharmaceutical mar
A data-driven comparison of the GCC's three largest pharmaceutical markets — UAE, Saudi Arabia, and Kuwait. Market size, growth rates, regulatory frameworks, pricing models, and strategic consideratio
A practical guide to pharmaceutical drug registration in Kuwait — covering MOH requirements, Ministerial Decree 302/2019, CTD documentation, local agent mandates, registration timelines, and GCC centr
Qatar is sequencing 350,000 genomes, funding CAR-T cell production at Sidra Medicine, and executing a National Health Strategy targeting 82.6-year life expectancy. With a pharma market growing at near
Kuwait is channeling a $10 billion healthcare budget, $608 million in hospital infrastructure, and its first major pharmaceutical factory into a Vision 2035-driven transformation. With partnerships sp
Egypt's healthcare sector is surging — a $5 billion pharma market growing at 3x the regional average, a tenfold increase in health spending to EGP 406 billion, MENA's largest drug manufacturing base g
From a $392 million oncology drug market to locally manufactured cancer therapies, Dubai's first integrated cancer hospital, and a $200 million precision oncology commitment — the UAE is rewriting its
深入解析中国2026年医疗健康市场全景，涵盖医保改革、创新药出海、AI医疗商业化、生物药增长及老龄化带来的医疗需求变革。为制药企业、投资者和行业从业者提供全面的市场洞察。
Saudi Arabia's SFDA granted landmark orphan drug designations in January 2026, signaling accelerated access to breakthrough therapies for rare disease patients. From Jascayd for pulmonary fibrosis to
The UK life sciences sector is undergoing a transformation driven by multi-omics and AI-integrated drug discovery. Effective pharmaceutical market research UK is essential for navigating the evolving
The SFDA's recent approval of Qfitlia for Hemophilia A and B marks a significant milestone in the Saudi Arabia pharmaceutical market. This siRNA-based therapy demonstrates the Kingdom's commitment to
Original physician surveys healthcare data reveals a critical 'trust gap' in AI diagnostics and telehealth integration. This report leverages healthcare market research to decode why 68% of clinicians
The FDA's February 2026 statement targeting non-FDA-approved GLP-1 drugs has sent shockwaves through the metabolic health sector. This update analyzes the enforcement surge against compounding pharmac
Navigating the MENA healthcare landscape requires specialized intelligence. We evaluate the top market research firms, including BioNixus, IQVIA, and Ipsos, to help life sciences leaders choose the ri
The rollout of the EU Joint Clinical Assessment (JCA) in 2026 is the single most disruptive event in EMEA market access history. This update breaks down how the new centralized clinical evaluation in
Physician engagement is reaching a saturation point. Discover how modern physician surveys healthcare strategies leverage behavioral economics and rapid-response tech to maintain high-quality data in
Saudi Arabia represents over 50% of the GCC pharmaceutical market. This guide covers SFDA registration requirements, Vision 2030 incentives, and proven market entry strategies for pharmaceutical compa
Comprehensive analysis of the UAE healthcare market landscape, emerging trends, and strategic opportunities for pharmaceutical companies.
Navigate pharmacoeconomic requirements and HTA frameworks across UAE, Saudi Arabia, and Kuwait markets.
How quantitative market research shapes pharmaceutical market access outcomes — physician surveys, payer evidence, and launch tracking for GCC and global teams.
Pharmaceutical market access in the UAE—reimbursement, formulary listing, and physician adoption—depends on evidence and stakeholder alignment. Market research shapes pricing, value stories, and launc
The UAE healthcare market, valued at USD 22 billion in 2024, represents one of the fastest-growing pharmaceutical markets in the Middle East. This comprehensive guide explores the methodologies, regul
Hub pages and guides commonly paired with these insights.
Country hubs, therapy areas, and research modules.
ExploreRankings, guides, and strategic market intelligence.
ExploreQuantitative, qualitative, access, and KOL programmes.
ExploreEvidence from recent pharma and healthcare engagements.
ExploreArticles span quantitative physician research, qualitative KOL work, GCC and EU market access, hospital adoption, regulatory updates, and launch strategy—written for commercial, medical, and access teams.
We add practical fieldwork-led articles as programs complete and markets shift. Subscribe via the site footer for monthly EMEA pharma research highlights.
Yes. Use the contact form with your therapy area, geography, and decision deadline—we typically respond with a tailored methodology outline within one business day.
Our team supports pharmaceutical companies with decision-ready insights across the Americas, Europe, and the Middle East using quantitative and qualitative methodologies.
US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323